PE20131024A1 - Composiciones basadas en glucocorticoides - Google Patents

Composiciones basadas en glucocorticoides

Info

Publication number
PE20131024A1
PE20131024A1 PE2012002189A PE2012002189A PE20131024A1 PE 20131024 A1 PE20131024 A1 PE 20131024A1 PE 2012002189 A PE2012002189 A PE 2012002189A PE 2012002189 A PE2012002189 A PE 2012002189A PE 20131024 A1 PE20131024 A1 PE 20131024A1
Authority
PE
Peru
Prior art keywords
release part
composition
glucocorticoids
glucocorticoid
compositions based
Prior art date
Application number
PE2012002189A
Other languages
English (en)
Inventor
Thomas Hedner
Ulrika Sigrida Helena Simonsson
Gudmundur Johannsson
Hans Lennernas
Stanko Skrtic
Original Assignee
Duocort Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42953726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duocort Pharma Ab filed Critical Duocort Pharma Ab
Publication of PE20131024A1 publication Critical patent/PE20131024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION DE GLUCOCORTICOIDES QUE COMPRENDE UNA PARTE DE LIBERACION INMEDIATA Y UNA PARTE DE LIBERACION EXTENDIDA, DONDE LA PROPORCION DE GLUCOCORTICOIDE EN LA PARTE DE LIBERACION INMEDIATA Y LA DE LIBERACION EXTENDEIDA SE ENCUENTRA EN EL RANGO DE 1:1 A 0,01:1. LA COMPOSICION TAMBIEN PUEDE CONTENER HIPROMELOSA, CELULOSA MICROCRISTALINA, ALMIDON, SILICE COLOIDAL ANHIDRO, ESTEARATO DE MAGNESIO, ENTRE OTROS. EL GLUCOCORTICOIDE ES HIDROCORTISONA. DICHA COMPOSICION ES UTIL EN LA TERAPIA DE REEMPLAZO EN ENFERMEDADES TALES COMO INSUFICIENCIA RENAL CRONICA O TEMPORAL
PE2012002189A 2010-05-20 2011-05-18 Composiciones basadas en glucocorticoides PE20131024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000442 2010-05-20

Publications (1)

Publication Number Publication Date
PE20131024A1 true PE20131024A1 (es) 2013-10-10

Family

ID=42953726

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002189A PE20131024A1 (es) 2010-05-20 2011-05-18 Composiciones basadas en glucocorticoides

Country Status (15)

Country Link
US (2) US20130209565A1 (es)
EP (1) EP2571505B1 (es)
JP (1) JP2013526552A (es)
KR (1) KR20130099815A (es)
CN (1) CN102933218A (es)
AU (1) AU2011254959A1 (es)
BR (1) BR112012029466A2 (es)
CA (1) CA2799820A1 (es)
CL (1) CL2012003152A1 (es)
CO (1) CO6660433A2 (es)
IL (1) IL223000A0 (es)
MX (1) MX337429B (es)
PE (1) PE20131024A1 (es)
SG (2) SG185457A1 (es)
WO (1) WO2011144327A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2016196687A1 (en) * 2015-06-01 2016-12-08 Massachusetts Institute Of Technology System and method for neuroendocrine control
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
CN108553436A (zh) * 2018-06-08 2018-09-21 华益药业科技(安徽)有限公司 一种20mg氢化可的松片处方和工艺规程
WO2020037248A1 (en) * 2018-08-17 2020-02-20 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
NZ602010A (en) * 2009-04-07 2013-11-29 Duocort Pharma Ab Improved glucocorticoid therapy

Also Published As

Publication number Publication date
AU2011254959A1 (en) 2013-01-10
CO6660433A2 (es) 2013-04-30
SG10201506611XA (en) 2015-09-29
EP2571505A1 (en) 2013-03-27
EP2571505B1 (en) 2016-07-06
WO2011144327A1 (en) 2011-11-24
CN102933218A (zh) 2013-02-13
MX2012013254A (es) 2013-01-24
CA2799820A1 (en) 2011-11-24
MX337429B (es) 2016-03-04
KR20130099815A (ko) 2013-09-06
CL2012003152A1 (es) 2013-07-12
SG185457A1 (en) 2012-12-28
US20150209375A1 (en) 2015-07-30
US20130209565A1 (en) 2013-08-15
IL223000A0 (en) 2013-02-03
BR112012029466A2 (pt) 2017-03-01
JP2013526552A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
PE20131024A1 (es) Composiciones basadas en glucocorticoides
BR112012022774A2 (pt) Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
BR112016025331A2 (pt) composições antimicrobianas
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
GB2550301A (en) Antimicrobial fibers and compositions
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
BR112015022627A2 (pt) composição hidráulica com tempo de abertura prolongado
MY165124A (en) Semifluorinated alkane compositions
BR212012031500U2 (pt) composições sólidas
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
PE20140040A1 (es) Composicion farmaceutica que comprende un inhibidor de la actividad de mek
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
BR112012017298A2 (pt) composições de polímeros microbicidas e uso das mesmas
BR112015010678A2 (pt) compostos de junta ready-mix usando carboximetilcelulose substituída não uniformemente
BR112014027371A2 (pt) variantes de enzima aprimoradas
BR112016009623A2 (pt) copolímero de acrilato reticulado intumescente em álcali, métodos para fabricar o mesmo e composição compreendendo o mesmo
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
MX2012008930A (es) Composiciones de etanol.
BR112015001728B8 (pt) composições de condicionador
IN2012DE00497A (es)
PH12018501593A1 (en) Plasterboard
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
RS54449B1 (en) AGOMELATIN HYDROBROMIDE HYDRAUL AND ITS PREPARATION
EA201270547A1 (ru) Фармацевтическая композиция
PE20110559A1 (es) (4bR,6R,7R,8aS)-4b-BENCIL-6,7-DIHIDROXI-6-METIL-N-(2-METILPIRIDIN-3-IL)-10-OXO-7-FENIL-4b,5,6,7,8,8a,9,10-OCTAHIDROFENANTRENO-2-CARBOXAMIDA COMO MODULADOR DEL RECEPTOR GLUCOCORTICOIDE

Legal Events

Date Code Title Description
FD Application declared void or lapsed